ABT Stock Risk & Deep Value Analysis
Abbott Laboratories
DVR Score
out of 10
What You Need to Know About ABT Stock
We analyzed Abbott Laboratories using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
ABT Risk Analysis & Red Flags
What Could Go Wrong
The recent $20 billion increase in debt to finance the Exact Sciences acquisition significantly alters Abbott's balance sheet. If the integration proves more challenging than anticipated, or if the acquired assets underperform revenue expectations, the increased interest expense could pressure earnings and cash flow, potentially leading to a re-evaluation of its credit rating or capital allocation strategy.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Low
Competitive
Medium
Execution
Low
Regulatory
Low
Red Flags
- ⚠
Total debt increased by $20 billion via senior notes in March 2026, impacting financial leverage.
- ⚠
Q4 2025 revenue missed Wall Street estimates, indicating potential challenges in some segments.
- ⚠
Nutrition segment is challenged in H1 2026 due to price cuts, potentially impacting near-term organic growth.
Upcoming Risk Events
- 📅
Exact Sciences acquisition integration challenges or slower than expected synergies
- 📅
Slower growth in Nutrition segment due to price cuts
When to Reconsider
- 🚪
Exit if the debt-to-equity ratio significantly deteriorates or if free cash flow turns negative for two consecutive quarters.
- 🚪
Sell if competitive pressures or regulatory changes lead to sustained market share loss in core franchises like FreeStyle Libre.
- 🚪
Significant downward revision in analyst consensus EPS or revenue forecasts for FY2026/FY2027.
Unlock ABT Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Abbott Laboratories represents a resilient, diversified healthcare powerhouse poised for steady, incremental growth, supported by strategic acquisitions like Exact Sciences and continued innovation in high-demand areas such as diabetes care and structural heart. While not a 10x growth opportunity due to its mature size, it offers stability, a solid dividend, and long-term capital appreciation potential in a defensive sector.
Is ABT Stock Undervalued?
Unlock the full AI analysis for ABT
Get the complete DVR score, risk analysis, and more
ABT Price Targets & Strategy
12-Month Target
$132.00
Bull Case
$145.00
Bear Case
$95.00
Valuation Basis
Based on analyst consensus price target of $132, implying a 25.7x forward P/E on estimated FY26 EPS of $5.13, consistent with its strategic value.
Entry Strategy
Dollar-cost average between $100-$105, capitalizing on the current 26% discount from peak prices.
Exit Strategy
Consider taking profits above $135; establish a stop-loss at $98 to protect against significant downside.
Portfolio Allocation
2-4% for moderate risk tolerance, given its stability but limited exponential upside.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ABT Financially Healthy?
Valuation
P/E Ratio
28.30
Forward P/E
18.80
PEG Ratio
-0.40
Price/Sales
4.10
Profitability
Gross Margin
57.00%
Operating Margin
21.60%
Net Margin
14.70%
Return on Equity
13.00%
Revenue Growth
4.40%
EPS
$0.00
Balance Sheet
Current Ratio
1.60
Debt/Equity
0.27
Cash Flow
Free Cash Flow
$7.26B
Does ABT Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Expanding
Moat Sources
4 Identified
Abbott's wide moat is durable due to continuous innovation protected by patents, high switching costs for critical medical devices, and the strong brand loyalty in a highly regulated and stable industry. The Exact Sciences acquisition further solidifies its position in diagnostics.
Moat Erosion Risks
- •Rapid technological advancements by competitors that could bypass existing IP.
- •Increased regulatory scrutiny or pricing pressures on medical devices and diagnostics.
- •Loss of key patents without sufficient pipeline to replace revenue.
ABT Competitive Moat Analysis
Sign up to see competitive advantages
ABT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - Typically attracts long-term dividend investors rather than meme stock or speculative interest.
Institutional Sentiment
Positive - Analyst consensus price target of $132 suggests upside; no recent downgrades reported.
Insider Activity (Form 4)
A Form 4 filing occurred on March 25, 2026 (specifics not detailed in provided data), but no CEO/CFO buys/sells flagged in particular.
Options Flow
Normal options activity for a large-cap healthcare company, no unusual speculative positioning flagged.
Earnings Intelligence
Next Earnings
2026-04-16
Surprise Probability
Medium
Historical Earnings Pattern
Abbott typically reacts modestly to earnings, with significant movements only on substantial beats/misses or major guidance changes. Stability rather than volatility is the norm.
Key Metrics to Watch
Competitive Position
Top Competitor
JNJ
Market Share Trend
Stable to Gaining, particularly in diabetes care (FreeStyle Libre) and diagnostics (enhanced by Exact Sciences acquisition).
Valuation vs Peers
Trading at a slight premium on forward P/E (25.85) compared to some diversified healthcare peers, justified by its strong device pipeline and established market leadership.
Competitive Advantages
- •Broad and diversified product portfolio across multiple high-growth healthcare segments.
- •Strong brand recognition and established global distribution network.
- •Extensive intellectual property and R&D capabilities, particularly in medical devices and diagnostics.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ABT Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (April 16, 2026)
- •Early insights into Exact Sciences acquisition integration
Medium-Term (6-18 months)
- •Continued low-to-mid teens growth of FreeStyle Libre CGM
- •Synergies and expanded market reach from Exact Sciences integration
Long-Term (18+ months)
- •Further expansion into global diagnostics and structural heart markets
- •Innovation in new medical device and nutrition segments
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ABT?
- ✓
Acceleration in FreeStyle Libre adoption and international expansion.
- ✓
Successful integration and synergy realization from the Exact Sciences acquisition.
Bull Case Analysis
See what could go right with Premium
Competing with ABT
See how Abbott Laboratories compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Abbott Laboratories ABT | $182.2B | 2.2 | 28.3 | $44.3B | 14.7% | 4.4% | |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Abbott Laboratories Makes Money
Abbott Laboratories is a global healthcare company that develops, manufactures, and sells a diverse range of healthcare products. It operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company generates revenue by selling these products to hospitals, laboratories, clinics, retailers, and directly to consumers worldwide. Its business model relies on continuous innovation, strong brand reputation, vast distribution networks, and the high switching costs associated with its medical devices and diagnostic solutions, which ensures consistent demand and recurring revenue.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Abbott Laboratories (ABT)?
As of April 6, 2026, Abbott Laboratories has a DVR Score of 2.2 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Abbott Laboratories?
Abbott Laboratories's market capitalization is approximately $182.2B..
What is the risk level for ABT stock?
Our analysis rates Abbott Laboratories's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ABT?
Abbott Laboratories currently has a price-to-earnings (P/E) ratio of 28.3. This is in line with broader market averages.
Is Abbott Laboratories's revenue growing?
Abbott Laboratories has reported revenue growth of 4.4%. The company is growing at a moderate pace.
Is ABT stock profitable?
Abbott Laboratories has a profit margin of 14.7%. The company is profitable but margins are modest.
How often is the ABT DVR analysis updated?
Our AI-powered analysis of Abbott Laboratories is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ABT (Abbott Laboratories) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.